Grifols (GIFLF) Cash from Investing Activities Growth (1y) (2011 - 2020)
Grifols (GIFLF) Cash from Investing Activities Growth (1y) (2011 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
-37.17% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
-16.79% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-250.17% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
21.90% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-586.62% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
-60.18% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
526.51% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-76.02% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
73.75% |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
56.61% |
| Dec 31, 2019 |
-157.70% |
| Mar 31, 2019 |
-340.75% |
| Dec 31, 2018 |
-68.90% |
| Jun 30, 2018 |
-676.00% |
| Mar 31, 2018 |
-93.95% |
| Dec 31, 2017 |
2,116.99% |
| Dec 31, 2016 |
90.81% |
| Sep 30, 2016 |
-1,045.50% |
| Mar 31, 2013 |
116,845.09% |
| Dec 31, 2012 |
-114.42% |
| Sep 30, 2012 |
-99.62% |
| Jun 30, 2012 |
100.08% |
| Mar 31, 2012 |
100.28% |
| Dec 31, 2011 |
-47.06% |
| Sep 30, 2011 |
13,951.87% |
